PGTx believes it can improve global health in both developing and developed countries consistent with the U.N. Sustainable Development Goals. Our vaccine technologies originated in animal health, which is required to be low-cost and administered under challenging circumstances. The principle of cost-effective innovation runs through PGTx’s vaccines for human health. For the lower income countries where cost is an issue, the vaccines will be manufactured and distributed through multinational health organizations, local governments and NGO health networks. For these vaccines, PGTx will pursue a pricing policy consistent with achieving social enterprise goals and ensuring financial sustainability. For commercial markets including the travelers’ market and military applications, a conventional licensing model will be followed. Revenues generated from these markets will be the major drivers of ROI.